Bold Moves

Win the digital race in pharma

Deliver first-in-class science

Pfizer is working with Wellcome to help tackle the growing public health crisis of antimicrobial resistance (AMR)

As part of our longstanding history of fighting infectious diseases and reducing health disparities for people around the world, Pfizer announced a partnership with Wellcome, an independent foundation, to help tackle the growing public health crisis of AMR.

AMR occurs when bacteria evolve to resist the effectiveness of antibiotics, making previously treatable diseases difficult or impossible to treat. Without action, it is expected to lead to the deaths of 10 million people annually by 2050.1

Countries in sub-Saharan Africa and other low- and middle-income countries already have a high burden of infectious diseases, and experts anticipate they will be disproportionately affected by AMR.

Surveillance is a vital tool for clinicians and public health officials to slow the rise of AMR. However, as recently as 2017, nearly half of the countries in Africa didn’t have comprehensive local data on AMR.2 These challenges make it difficult for countries to implement infection control programs and inform the appropriate use of anti-infectives.​​​​​​​​​​​​​​

To address these issues, Pfizer and Wellcome launched Surveillance Partnership to Improve Data for Action on Antimicrobial Resistance (SPIDAAR), a public-private research collaborative with governments and health authorities in four countries in sub-Saharan Africa.

This program brings together resources and expertise of industry, international non-governmental organizations and governments to support improved AMR surveillance and access to actionable data. Program data will be made available on Pfizer’s open-source ATLAS database, as well as on Wellcome’s AMR Register. Created more than 15 years ago, ATLAS is the only industry-led, public access platform that includes both antifungal and antibiotic resistance data.​​​​​​​

The first stage of the collaboration began in July 2019, with Pfizer and Wellcome working with government teams to identify health facilities in Ghana, Kenya, Malawi and Uganda. The next phase will initiate a surveillance program at select hospitals in these countries, where clinical isolates will be collected from infected hospitalized patients and tested for antimicrobial susceptibility.

Microbiologist examines isolates at laboratory in Kenya.



2                      ​​​​​​​

Discover more

Advances for a Potential First-in-Class Chronic OA Pain Treatment

Advancing Breakthroughs for Patients With NASH

Eucrisa, Now Starring Jessica Simpson

Working for Patients with Alopecia Areata

Advancing a Potential Breakthrough for Moderate to Severe Atopic Dermatitis

A Potentially Practice-Changing Approval in Advanced Urothelial Cancer

Addressing an Unmet Need for Certain Patients With BRAF-Mutant mCRC

Learning From Early Breast Cancer Studies to Drive Oncology Research Forward

Cancer Doesn’t Wait: Supporting Screenings During COVID-19

Positive Phase 1/2 Data at One Year for Hemophilia A Gene Therapy

Investigational Gene Therapy for Duchenne Muscular Dystrophy Achieves Exciting Milestones in 2020

Pfizer Vaccines Pipeline Includes Six Late-Stage Candidates

Pfizer Vaccines Launches​​​​​​​ Global Centers of Excellence Network

Progressing Maternal Vaccination Against Respiratory Syncytial Virus

Pfizer Pledges $100 Million Into New AMR Industry Fund

Partnering with Wellcome to Combat AMR in Sub-Saharan Africa

Expanding Access in China Through Health Insurance Innovation

Pfizer Invests in Biotechnology Innovation through the Pfizer Breakthrough Growth Initiative

Hospital Donations for COVID-19 Response

Pfizer Partners with BioNTech to Advance & Supply COVID-19 Vaccine​​​​​​​

Delivering on the Promise of Biosimilars

Driving Diversity in Our Research and Development​​​​​​​

Site Feature: Puurs, Belgium 

PGS Ingenuity Solves COVID-19 Cold Chain Storage Challenge​​​​​​​

Pfizer and Gilead Sciences Agree to Manufacture and Supply Remdesivir​​​​​​​

Key Medicine Supply and Public Policy During COVID-19

Pfizer Stands with Science

Five-Point Plan for Unprecedented Collaboration

COVID-19 Updates

Read the latest information about Pfizer’s COVID-19 vaccine on



Join the Conversation

Additional Information

Useful Links

The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries.

Copyright © 2020-2021 Pfizer Inc.
All rights reserved

Explore our stories